Novartis passes 300m milestone for childhood malaria treatment donations

Pharmaceutical Company Product News

Novartis has announced that it has now provided 300 million child-friendly antimalarial treatments without profit since 2009.

The passing of this delivery milestone is indicative of the work the company has done to reduce the disease burden for children in more than 30 malaria-endemic countries over the last few years.

“Novartis has reached a delivery milestone of 300 million paediatric antimalarial treatments supplied without profit since 2009.“

Its Coartem Dispersible product is the first artemisinin-combination therapy developed by Novartis in collaboration with Medicines for Malaria Venture specifically to meet the needs of children, and has become the standard of care in many of these countries.

Thanks to innovations such as this, the malaria death rate for children under the age of five years has fallen by 71 percent since 2000, but further efforts will be needed to wipe the disease out completely.

Joseph Jimenez, chief executive officer of Novartis, said: "We are proud of the part we have played in helping to reduce childhood deaths from malaria, and we continue to provide medicine at no profit to people who need it."

Infants and young children remain among those at greatest risk of contracting malaria, with 70 percent of malaria deaths occurring in children under the age of five.

See all the latest jobs in Pharmaceutical
Return to news